PD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study. (20th June 2018)

Record Type:: Journal Article
Title:: PD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study. (20th June 2018)
Main Title:: PD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study
Authors:: Modest, D
von Weikersthal, L Fischer
Decker, T
Vehling-Kaiser, U
Uhlig, J
Schenk, M
Freiberg-Richter, J
Peuser, B
Denzlinger, C
Reddemann, C Peveling genannt
Graeven, U
Schuch, G
Schwaner, I
Stahler, A
Jung, A
Kirchner, T
Held, S
Stintzing, S
Giessen-Jung, C
Heinemann, V
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 5
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 5
Issue Display:: Volume 29, Issue 5 (2018)
Year:: 2018
Volume:: 29
Issue:: 5
Issue Sort Value:: 2018-0029-0005-0000
Page Start:
Page End:
Publication Date:: 2018-06-20
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy150.019 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12246.xml